Echo Street Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-3,268
| Closed | -$368K | – | 283 |
|
|
2023
Q3 | $368K | Buy |
+3,268
| New | +$368K | ﹤0.01% | 336 |
|
|
2023
Q2 | – | Sell |
-3,073
| Closed | -$311K | – | 555 |
|
|
2023
Q1 | $311K | Buy |
3,073
+1,037
| +51% | +$105K | ﹤0.01% | 371 |
|
|
2022
Q4 | $243K | Buy |
+2,036
| New | +$243K | ﹤0.01% | 438 |
|
|
2022
Q2 | – | Sell |
-5,536
| Closed | -$519K | – | 654 |
|
|
2022
Q1 | $519K | Sell |
5,536
-2,763
| -33% | -$259K | ﹤0.01% | 391 |
|
|
2021
Q4 | $707K | Buy |
+8,299
| New | +$707K | ﹤0.01% | 336 |
|
|
2021
Q3 | – | Sell |
-8,724
| Closed | -$849K | – | 705 |
|
|
2021
Q2 | $849K | Buy |
+8,724
| New | +$849K | 0.01% | 226 |
|